Eckert & Ziegler stock at EUR 13.35, up 0.38%
Published on 11/02/2026 at 08:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSIsotope applications remain central
- Eckert & Ziegler supplies isotope components for medical, scientific and measurement applications.
- The group operates through its Medical and Isotope Products segments and is scheduled to report on November 12, 2026.
Eckert & Ziegler stock traded at 13.35 euros on Lang & Schwarz at 07:58 CET on Monday, November 2, 2026, 0.38 percent above the Xetra close of Friday, October 30, 2026 at EUR 13.30.
The company focuses on isotope technology for cancer treatment, industrial radiometry, and nuclear medicine diagnostics and therapy. Its operating business is divided into the Medical and Isotope Products segments.
According to the Eckert & Ziegler investor page, the group generated EUR 312.0 million in revenue in 2025 and reported adjusted EBIT of EUR 77.7 million. The company had 1,116 employees in 2025.
Investors are focused on the group's radiopharmaceutical activities after Eckert & Ziegler received GMP authorization for routine Actinium-225 production, according to a company-related report published on October 30. The approval supports clinical supply and future capacity plans.
Investors can follow the real-time quote of Eckert & Ziegler stock during the session.
The broader German market context is covered in the DAX market overview.
More updates are available in more news and analyses on Eckert & Ziegler stock.
